{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:34:30Z","timestamp":1788042870540,"version":"build-2784847793"},"reference-count":42,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNS"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:sec>\n<jats:title>Object<\/jats:title>\n<jats:p>Oligodendrogliomas are rare primary brain tumors. They comprise approximately 5 to 33% of all glial tumors but differ from astrocytomas by being associated with a more favorable prognosis, making their correct identification important. Allelic loss of chromosome arms 1p and 19q is found in a substantial subpopulation of tumors with an oligodendroglioma phenotype. Anaplastic oligodendrogliomas with allelic loss of 1p have been associated with chemosensitivity and a longer patient survival period.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Oligodendroglial neoplasms were studied using fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissue specimens; reference and target probe sets were used to map the telomeric regions of 1p and 19q. The results were correlated with the clinical characteristics of patients treated at our institution between 1993 and 2003.<\/jats:p>\n<jats:p>Data obtained in 96 patients were analyzed. This included 63 patients (65.6%) with World Health Organization (WHO) Grade II oligodendroglioma, 22 (23%) with Grade III oligodendroglioma, and 11 (11.4%) with mixed oligoastrocytoma. Analysis of 1p in patients with pure oligodendroglioma revealed a loss of 1p in 42 patients (49.4%). In 46 of these patients 19q was lost and in 70 (82.3%) there was concordance for combined loss or retention of both 1p and 19q (p &lt; 0.0001). Patients with oligodendroglioma in whom a loss of 1p was present fared significantly better, and this outcome was unrelated to the treatment modality or WHO grade, compared with patients in whom 1p was intact (p &lt; 0.05).<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>To the authors\u2019 knowledge, this study includes the largest published series of WHO Grade II oligodendroglioma and 1p analysis. The results suggest that the association between long-term survival and 1p loss in oligodendroglioma is unrelated to treatment. The authors of further prospective studies may better determine the true value of the allelic loss of 1p and its implication for clinical decision making.<\/jats:p><\/jats:sec>","DOI":"10.3171\/jns.2006.104.4.542","type":"journal-article","created":{"date-parts":[[2008,1,24]],"date-time":"2008-01-24T12:34:12Z","timestamp":1201178052000},"page":"542-550","source":"Crossref","is-referenced-by-count":41,"title":["The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making"],"prefix":"10.3171","volume":"104","author":[{"given":"Andrew A.","family":"Kanner","sequence":"first","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Staugaitis","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias A.","family":"Castilla","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Chernova","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Prayson","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Vogelbaum","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Stevens","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Peereboom","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Suh","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Yuan","family":"Lee","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond R.","family":"Tubbs","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene H.","family":"Barnett","sequence":"additional","affiliation":[{"name":"The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center; Departments of Neurosurgery, Anatomic Pathology, Neurosciences, Radiation Oncology, and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and Department of Neurosurgery, Tel Aviv Sourasky Medical Center, University of Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-1040542","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1212\/WNL.59.1.40","article-title":"Late cognitive and radiographic changes related to radiotherapy: initial prospective findings","volume":"59","year":"2002"},{"key":"b2-1040542","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0360-3016(00)00703-3","article-title":"Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas","volume":"48","year":"2000"},{"key":"b3-1040542","series-title":"Int J Cancer","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ijc.2910570207","article-title":"Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors","volume":"57","year":"1994"},{"key":"b4-1040542","series-title":"Am J Pathol","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0002-9440(10)65134-6","article-title":"Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization","volume":"155","year":"1999"},{"key":"b5-1040542","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/jnci\/90.19.1473","article-title":"Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas","volume":"90","year":"1998"},{"key":"b6-1040542","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/cncr.11632","article-title":"Cyclooxygenase-2 in oligodendroglial neoplasms","volume":"98","year":"2003"},{"key":"b7-1040542","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1227\/00006123-199412000-00003","article-title":"Cerebral oligodendroglioma: prognostic factors and life history","volume":"35","year":"1994"},{"key":"b8-1040542","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1023\/A:1022580610598","article-title":"Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results","volume":"61","year":"2003"},{"key":"b9-1040542","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W","article-title":"Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas","volume":"79","year":"1997"},{"key":"b10-1040542","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/jnen\/63.4.314","article-title":"Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas","volume":"63","year":"2004"},{"key":"b11-1040542","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/00006123-199912000-00001","article-title":"Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment","volume":"45","year":"1999"},{"key":"b12-1040542","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0360-3016(92)90942-B","article-title":"The role of postoperative irradiation in the treatment of oligodendroglioma","volume":"30","year":"1994"},{"key":"b13-1040542","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/jnen\/64.1.10","article-title":"Molecular genetic analysis of oligodendroglial tumors","volume":"64","year":"2005"},{"key":"b14-1040542","series-title":"Anticancer Res","first-page":"617","article-title":"Propylthiouracil-induced chemical hypothyroidism with high dose tamoxifen prolongs survival in recurrent high grade glioma: a Phase I\/II study","volume":"23","year":"2003"},{"key":"b15-1040542","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1200\/JCO.2004.10.169","article-title":"Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions","volume":"22","year":"2004"},{"key":"b16-1040542","series-title":"Clin Cancer Res","first-page":"839","article-title":"Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis","volume":"7","year":"2001"},{"key":"b17-1040542","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3171\/jns.2000.92.6.0983","article-title":"Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss","volume":"92","year":"2000"},{"key":"b18-1040542","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0360-3016(01)02692-X","article-title":"Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis","volume":"52","year":"2002"},{"key":"b19-1040542","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0360-3016(96)00352-5","article-title":"A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844","volume":"36","year":"1996"},{"key":"b20-1040542","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3171\/jns.2001.95.5.0735","article-title":"Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome","volume":"95","year":"2001"},{"key":"b21-1040542","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1023\/A:1006402614838","article-title":"Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme","volume":"48","year":"2000"},{"key":"b22-1040542","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3171\/jns.1987.67.2.0224","article-title":"Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma","volume":"67","year":"1987"},{"key":"b23-1040542","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/00005072-199710000-00003","article-title":"Molecular genetic evidence for subtypes of oligoastrocytomas","volume":"56","year":"1997"},{"key":"b24-1040542","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/cncr.21338","article-title":"The prognostic impact of histology and 1p\/19q status in anaplastic oligodendroglial tumors","volume":"104","year":"2005"},{"key":"b25-1040542","series-title":"Brain Pathol","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1750-3639.1998.tb00191.x","article-title":"Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes","volume":"8","year":"1998"},{"key":"b26-1040542","series-title":"Neurooncol","first-page":"61","article-title":"Treatment of oligodendroglioma: an update","volume":"1","year":"1999"},{"key":"b27-1040542","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3171\/jns.1998.89.1.0042","article-title":"Systemic T cell adoptive immunotherapy of malignant gliomas","volume":"89","year":"1998"},{"key":"b28-1040542","series-title":"Clin Cancer Res","first-page":"2209","article-title":"T cell adoptive immunotherapy of newly diagnosed gliomas","volume":"6","year":"2000"},{"key":"b29-1040542","series-title":"Pathology and Genetics of Tumours of the Nervous System","first-page":"56","article-title":"Oligodendroglioma and anaplastic oligodendroglioma","year":"2000"},{"key":"b30-1040542","series-title":"Am J Pathol","first-page":"1175","article-title":"Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p","volume":"145","year":"1994"},{"key":"b31-1040542","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/jnen\/61.1.58","article-title":"Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade \u201coligodendroglioma\u201d","volume":"61","year":"2002"},{"key":"b32-1040542","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/jnen\/61.4.321","article-title":"Impact of genotype and morphology on the prognosis of glioblastoma","volume":"61","year":"2002"},{"key":"b33-1040542","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3171\/jns.1992.76.3.0428","article-title":"Oligodendrogliomas: the Mayo Clinic experience","volume":"76","year":"1992"},{"key":"b34-1040542","series-title":"Oncogene","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1038\/sj.onc.1202759","article-title":"Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype","volume":"18","year":"1999"},{"key":"b35-1040542","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1200\/JCO.2000.18.3.636","article-title":"Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas","volume":"18","year":"2000"},{"key":"b36-1040542","series-title":"J Neurol","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s004150050587","article-title":"A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors","volume":"247","year":"2000"},{"key":"b37-1040542","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1023\/A:1025689004046","article-title":"Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity","volume":"64","year":"2003"},{"key":"b38-1040542","series-title":"Clin Cancer Res","first-page":"196","article-title":"Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors","volume":"8","year":"2002"},{"key":"b39-1040542","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1212\/WNL.57.2.340","article-title":"Temozolomide chemotherapy in recurrent oligodendroglioma","volume":"57","year":"2001"},{"key":"b40-1040542","series-title":"Glia","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/glia.440150312","article-title":"Molecular pathways in the formation of gliomas","volume":"15","year":"1995"},{"key":"b41-1040542","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1158\/1078-0432.CCR-04-0681","article-title":"Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component","volume":"10","year":"2004"},{"key":"b42-1040542","series-title":"Cancer Res","first-page":"6713","article-title":"Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms","volume":"61","year":"2001"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/104\/4\/article-p542.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/104\/4\/article-p542.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/104\/4\/article-p542.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T18:09:50Z","timestamp":1679854190000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/104\/4\/article-p542.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":42,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3171\/jns.2006.104.4.542","relation":{},"ISSN":["0022-3085"],"issn-type":[{"value":"0022-3085","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}